Literature DB >> 7298586

Withdrawal and pseudowithdrawal from diazepam therapy.

A Winokur, K Rickels.   

Abstract

We present two cases from a double-blind placebo-controlled study of diazepam in treatment of anxiety that illustrate the importance of attitudes of patients and physicians towards use of diazepam. Patient 1 exhibited symptoms of nausea, depression and increased anxiety, which both he and the research psychiatrist interpreted as a withdrawal reaction. Examination of the treatment code, however, revealed that the patient had been kept on the same dose of diazepam throughout this period and that he had maintained therapeutic plasma diazepam levels. This case illustrated a "pseudowithdrawal reaction" in a patient being maintained on active drug treatment. Patient 2 benefited remarkably from maintenance diazepam therapy and had manifested considerable anxiety during double-blind placebo substitution but his private physician expressed great reluctance to continue this treatment regimen because he had been influenced by unfavorable publicity. Further information on maintenance diazepam therapy and problems with withdrawal must be obtained under carefully controlled conditions.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7298586

Source DB:  PubMed          Journal:  J Clin Psychiatry        ISSN: 0160-6689            Impact factor:   4.384


  4 in total

Review 1.  Is there still a role for benzodiazepines in general practice?

Authors:  M B King
Journal:  Br J Gen Pract       Date:  1992-05       Impact factor: 5.386

2.  Hospital admission and start of benzodiazepine use.

Authors:  K Woodcock
Journal:  BMJ       Date:  1992-05-02

3.  Rebound insomnia in normals and patients with insomnia after abrupt and tapered discontinuation.

Authors:  T Roehrs; L Merlotti; F Zorick; T Roth
Journal:  Psychopharmacology (Berl)       Date:  1992       Impact factor: 4.530

4.  Chronic use of benzodiazepines and psychomotor and cognitive test performance.

Authors:  I Lucki; K Rickels; A M Geller
Journal:  Psychopharmacology (Berl)       Date:  1986       Impact factor: 4.530

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.